BioSpace News Archive

Mallinckrodt’s Specialty Generics division honored with Collaborative Innovation Leadership Award for its COVID-19 pandemic response

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day on April 1, 2021.

Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families

Theralase Technologies Inc. announced today the launch of the Theralase® Anti-Cancer Therapy (“ACT”) research centre located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network (“UHN”), Toronto.

Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19 Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma If approved , Opdivo would be the first adjuvant immunotherapy option for patients with muscle-invasive urothelial carcinoma in Europe

CytoSorbents Corporation announces the lease of its new global headquarters in Princeton, NJ. On March, 26, 2021, the company entered into a new agreement with National Business Parks to lease approximately 48,500 square feet located at 305 College Road East at Princeton Forrestal Village in Princeton, New Jersey.

Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Gary Goldenberg, M.D., Verrica’s Chief Medical Officer, has been elected as an active member into the American Dermatological Association (ADA).

-- Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases -- Biohaven and Royalty Pharma have previously announced a funding agreement to advance the clinical development of intranasal and oral formulations of zavegepant

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today that Pam Contag, Ph.D., President and Chief Executive Officer of BioEclipse, will present at the Spring 2021 virtual meeting